ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: PB1163

    C20209T Prothrombin Gene Mutation in a Caucasian Woman with a History of Venous Thrombosis

    D. Jambou1, N. Saut2, V. Queyrel-Moranne3, A. Appert-Flory1, F. Fischer1, P. Suchon2, P. Toulon1

  • Abstract Number: PB0320

    Calculation of Fresh Frozen Plasma Amount to Correct Prolonged International Normalized Ratio

    L. Pinitsubsin1, Y. Chinthammitr2

  • Abstract Number: OC 70.1

    cAMP Prevents Antibody Induced Thrombus Formation in COVID-19

    J. Zlamal1, K. Althaus1, H. Jaffal1, H. Häberle2, L. Pelzl1, A. Singh1, A. Witzemann1, K. Weich1, M. Bitzer3, N. Malek3, S. Göpel3, H. Bösmüller4, M. Gawaz5, V. Mirakaj2, P. Rosenberger2, T. Bakchoul1,6

  • Abstract Number: PB1219

    Can Combining a Risk Score Derived from Ubiquitous Biomarkers with a Clinical Risk Assessment Model Better Predict 90-day Post-discharge Hospital-associated Venous Thromboembolism among Medical Patients?

    S. Woller1,2, S. Stevens1,2, J. Bledsoe1,3, J. Lloyd1, G. Snow1, M. Fazili1, L. Venner1, J. Christensen1, B. Horne1,3

  • Abstract Number: PB0604

    Can Plasminogen Activator Inhibitor 1 and Thrombin Activitable Fibrinolysis Inhibitor Explain Bleeding Phenotype in Hemophilia A?

    S. Elhefnawy1, M. Abd Elrehim2, M. Elhawy2.

  • Abstract Number: OC 65.1

    Cancer is Associated with an Increased Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2VASc Score ≤ 2

    A. Leader1,2, N. Mendelson Cohen3, S. Afek2,4, R. Jaschek3, A. Frajman2, O. Itzhaki Ben Zadok5,2, P. Raanani1,2, M. Lishner6,2, A. Tanay3, G. Spectre1,2

  • Abstract Number: PB0429

    Cangrelor Long Term Prescription, Several Scenarios: A Case Report Series

    O. Duranteau1, L. Abdennour1, M. Drir1, F. Clarencon1, V. Degos1

  • Abstract Number: PB0838

    Caplacizumab Rapidly Inhibits VWF-platelet Interaction: Pharmacodynamic Data from Healthy Volunteers and Patients with aTTP

    F. Callewaert1, J. Minkue Mi Edou2, R. de Passos Sousa3

  • Abstract Number: LPB0049

    Cardiovascular Outcomes in Patients with Essential Thrombocythemia: Analysis of the National Inpatient Sample (NIS)

    G. Tafur1, H. Saadaldin2,3, F. Velazquez4, E. Marinescu5, A. Tafur6,7

  • Abstract Number: PB1005

    Case Report: Skin Necrosis in setting of Heparin and Warfarin Exposure

    D.Z.S. Eng1, C.P. Coorey1, D. Hsu1, S. Mallik1

  • Abstract Number: OC 17.3

    Case-fatality Rate of Major Bleeding Events among Patients Treated with Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-eluting Stent: A Systematic Review and Meta-analysis

    T. Tritschler1, A. Patel2, N. Kraaijpoel3, P. Di Santo4, B. Hibbert4, G. Le Gal2, L. Castellucci2

  • Abstract Number: PB0808

    Catastrophic Thrombotic Syndrome in 8 Year Old Boy: Clinical Case Report

    Y. Kashpurenko1, K. Vilchevska1, I. Bakhchyvandzhy1

  • Abstract Number: PB0291

    CATS-MICA Score in Predicting Venous Thromboembolism in SARS-CoV-2-infected Cancer Patients

    D.S. Juliao Caamaño1, C.L. Jimenez1, C. Blanco Abad2, J.L. Catoya Villa2, A. Gutierrez ORtiz de la Tabla3, I. Aparicio Salcedo3, L. Ortega Moran3, M. Martin Jimenez3, A. Muñoz Martin3

  • Abstract Number: OC 42.2

    Cellular Factor XIII in Macrophage Derived Foam Cells

    L. Somodi1, H. Bárdos2, É. Katona1, B. Baráth1, G. Haramura1, E. Horváth3, A.-H. Shemirani1, L. Muszbek1

  • Abstract Number: LPB0076

    Cerebral Sinovenous Thrombosis and Asparaginase Re-exposure in Patients Aged 1 to 45 Years with Acute Lymphoblastic Leukemia: A NOPHO ALL2008 Study

    M.T. Skipper1, C.U. Rank2,3, L. Andrés-Jensen4, K. Schmiegelow4, B.K. Albertsen1,5, R. Tuckuviene6,4, NOPHO Thrombosis and Haemostasis Working group

  • Abstract Number: PO171

    Cerebral Thrombosis during Treatment of Childhood Acute Lymphoblastic Leukemia

    A. Canbolat Ayhan1

  • Abstract Number: PB0279

    Change in Platelet Indices in Patients with Coronavirus Infection Disease (COVID-19): A Reflection of Platelet Activation and Contribution to Immunothrombosis?

    M. Mezgebe1, B.F. Jacobson1, S. Louw1

  • Abstract Number: PB0425

    Changes in Plasminogen Binding and Cell Surface Properties in Streptococcus pyogenes in the Absence of Sortase A Are Due to Disruptions in Localization of M-protein

    B. Russo1,2, V. Ploplis1,2, F. Castellino1,2

  • Abstract Number: OC 65.2

    Changes in Prescription Patterns of Oral Anticoagulants and Clinical Outcomes among Newly Diagnosed Non-valvular Atrial Fibrillation Patients in the Netherlands

    Q. Chen1, M.M. Toorop1, S.C. Cannegieter1, W.M. Lijfering1

  • Abstract Number: PB0083

    Changes in the Global Hemostatic Profile after Subarachnoid Aneurismatic Hemorrhage

    K. Nanwani1, I. Fernandez2, E. Monzón2, R. Justo2, N. Butta2, M. Quintana1

  • Abstract Number: PB0529

    Changes in Treatment Patterns in Patients with Severe Haemophilia – a Longitudinal Analysis of the Austrian Haemophilia Registry

    D. Kraemmer1, V. Ritschl2, J. Rejtő1, C. Feistritzer3, S. Gallistl4, S. Jäger5, N. Jones6, A. Kurringer7, P. Neumeister8, J. Rettl9, G. Schuster10, R. Schwarz11, M. Sohm12, W. Streif13, T. Schindl14, T. Stamm2, K. Thom15, C. Male15, I. Pabinger1, C. Ay1

  • Abstract Number: PB0027

    Changes in Vascular Physiology in Patients with End Stage Renal Disease Compared to Patients with ESRD and Concomitant Cardiovascular Disease

    J. Goldstein1, R. Dieter1, K. Wieschhaus1, J. Fareed1

  • Abstract Number: PB1019

    Charactering the Role of TLT-1 in Inflammatory Pathogenesis of Obesity and Nonalcoholic Fatty Liver Disease (NAFLD)

    S. Branfield1, B. Nieves Lopez2, M. Poynter3, A.V. Washington1

  • Abstract Number: PB0025

    Characterisation of Patients with Peripheral Artery Disease at Increased Risk for Cardiovascular Events and Mortality

    B. Kremers1, J.-W. Daemen2, H. ten Cate1,2, H. Spronk1, B. Mees2, A. ten Cate-Hoek1,2

  • Abstract Number: PB0755

    Characteristics and Management of a Series of TAFRO Syndrome

    X. Ye1

  • Abstract Number: PB1091

    Characteristics and Outcomes of Patients on Concurrent Direct Oral Anticoagulants and Targeted Anticancer Therapies – TacDOAC Registry

    T.-F. Wang1, L. Baumann Kreuziger2, A. Leader3,4, G. Spectre3,4, M. Lim5, A. Gahagan6, R. Gangaraju6, K. Sanfilippo7, R. Mallick8, J. Zwicker9, M. Carrier1

  • Abstract Number: PB0927

    Characteristics and Treatment of Patients with von Willebrand Disease (VWD) in General Practice Settings in the United Kingdom

    P. Du1, K. Wilcox Hagberg2, S. Tzivelekis3, F. Truong Berthoz4, G. Özen5, S. Jick2,6

  • Abstract Number: PB0486

    Characteristics of Anti-drug Antibody against Emicizumab Analyzed Using Hemophilia A Patient-derived Plasma Samples

    R. Kawasaki1, M. Kaneda2, M. Noguchi1, N. Matsumoto1, H. Abe1, Y. Tashiro1, Y. Inokuchi1, H. Yasuno1, T. Soeda1, Y. Yoshimura1, T. Oka2

  • Abstract Number: LPB0125

    Characteristics of Pediatric Oncology Patients with Tumour Thrombus

    N. Samji1, A.F. Fajardo1, A.K. Chan1, M.D Bhatt1

  • Abstract Number: OC 31.4

    Characterization of a New Family with Lifelong Macrothrombocytopenia Caused by a Novel Nonsense Variant in TPM4

    A. Marín-Quílez1, C. Fernández-Infante1, M.Á. Manrique Gonzalo2, C. Llorente-González1, M. Millán-Salanova1, S. Santos-Mínguez1, C. Miguel-García1, I. Rodríguez-Iglesias1, F. López-Cadenas2, T. González2, V. Palma-Barqueros3, R. Benito1, M. Díez-Campelo2, J.R. González-Porras2, J.M. Hernández-Rivas1,2, M. Vicente-Manzanares1, J. Rivera3,4, J.M. Bastida2,4

  • Abstract Number: LPB0052

    Characterization of Andexanet Alfa-associated Heparin Resistance: Implications for Management

    N. Thalji1, C. Chabata2, P. Patel3, B. Sullenger2, R. Camire4

  • Abstract Number: OC 52.2

    Characterization of the Role of Integrin α5β1 in Platelet Function, Haemostasis and Arterial Thrombosis in Mice

    E. Janus-Bell1, A. Yakusheva1,2, N. Receveur1, U.M. Ahmed1, C. Mouriaux1, C. Bourdon1, M.A. Panteleev2, C. Gachet1, P.H. Mangin1

  • Abstract Number: LPB0042

    Characterization of Thrombotic Risk in Patients with Cancer

    J. Trujillo Santos1, M. Salgado2, I. García Escobar3, R. Molina4, A. Araújo5, E. Horváth6, R. Porta7, J.C. Benítez8, M. Lobo9, E. Martí10, F. Garicano11, M. Malheiro12, A.L. Costa13, A.C. Albuquerque14, M.J. Ribeiro15, B. Campos Balea16, A. Cañada Martínez17, E. Brozos18, M. Masvidal19, P. Cerezuela20, CARTAGO study group

  • Abstract Number: PB0752

    Chemotherapy Induced Thrombocytopenia: Is it Inducing Additional Social, Economic and Clinical Burden?

    N. Anwar1, N. Fatima1, H.-u.- Mujtaba1, T. Shamsi1

  • Abstract Number: PB0757

    Chemotherapy-induced Thrombocytopenia and Platelet Transfusions in Hematology/Oncology Practice

    L. Hambardzumyan1,2, A. Movsisyan1,2, M. Badikyan2,3, N. Martirosyan2,3, H. Khachatryan1,2, A. Sevoyan2, H. Grigoryan1,1,2, N. Martirosyan2,4, G. Tamamyan1,2,4, S. Danielyan2

  • Abstract Number: PB0782

    Children with Bleeding and Clotting Disorders: Reviewing Quality of Life Tools

    S. Jones1,2, J. Bushe1, H. David1, C. Dinh1, K. Kolosidhi1, D. Rai1, F. Newall2,1

  • Abstract Number: OC 53.2

    Children with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) Have a High Incidence of Acute Episodes: Data from the International Hereditary TTP Registry (IHTTP Registry)

    E. Tarasco1,2, K. Sakai3, S. Al Shanbary4, L. Bütikofer5, Y. El Chazli6, J.N George7, H. Hengartner8, S. Jalal9, P.N Knöbl10, E. Maaß11, S. Milanovich12, S. Perungo13, G. Sinkovits14, M. Steele15, A.S. von Krogh16,17, K. Wyatt18, B. Lämmle1,19, J.A. Kremer Hovinga1,2, other members Steering Committee international hTTP Registry

  • Abstract Number: PB0607

    Chinese Real-world Experience of Product Switching in Severe Hemophilia Patients: from rFVIII-FS(Kogenate®) to BAY 81-8973 (Kovaltry®)

    C. Rong1, Z. Shiqiu1, G. Hua1, L. Jia1, G. Jing1, Y. Ming2, Z. Hong2, Y. Lin2, Z. Xin3

  • Abstract Number: LPB0132

    Chronic Edible Dosing of Δ9-tetrahydrocannabinol (THC) in Non-human Primates Reduces Systemic Platelet Activity and Function

    S.E. Reitsma1, J. Johnson1, J. Pang1, I. Parra-Izquierdo1,2, H. Hara Sudhan Lakshmanan1, A.R. Melrose2,1, M. T. Hinds1, J.E. Aslan2,1, O.J. McCarty1, J.O. Lo3

  • Abstract Number: PB0756

    Chronic Myeloid Leukemia with Extreme Thrombocytosis as Unusual Initial Presentation

    N. Petkova1

  • Abstract Number: PB0311

    Circulating Biologic Markers of Endothelial Dysfunction in Chronic Myeloproliferative Neoplasms

    O. Smirnova1, N. Silina1, N. Korsakova1, O. Golovina1, E. Efremova1, M. Fominykh1, S. Voloshin1, L. Papayan1

  • Abstract Number: PB0294

    Circulating Biologic Markers of Endothelial Dysfunction in COVID-19 Patients

    O. Matvienko1, N. Korsakova1, O. Smirnova1, A. Lerner2, T. Shwedova2, O. Golovina1, L. Papayan1

  • Abstract Number: LPB0103

    Circulating Cellular Clusters Are Correlated with Thrombotic Complications and Clinical Outcomes in COVID-19

    A. Dorken Gallastegi1, L. Naar1, E.M. Van Cott1, R.P. Rosovsky1, D.J. Gregory1, D. Annamalai2, J. Lee1, H.M.A. Kaafarani1, G. Velmahos1, R.G. Tompkins1, G.H. Frydman1,2

  • Abstract Number: PB1119

    Circulating Extracellular Vesicles in Patients with Cancer and Venous Thromboembolism: A Systematic Review and Meta-analysis

    O. Varol1,2, D. Burger1,2, T. Tritschler3, P. Wells4

  • Abstract Number: PB0164

    Circulating Histones Are Associated with Disease Severity and Coagulopathy in COVID-19

    R.J Shaw1, J. Austin1, J. Taylor2, T. Dutt2, G. Wang1, S.T Abrams1, C.-H. Toh1

  • Abstract Number: OC 68.2

    Circulating Levels of Platelet, Endothelial and Red Blood Cell Microvesicles in COVID-19: Association with Biomarkers of Coagulation, Fibrinolysis and Angiogenesis

    M.S. Barbosa1, F. Lima1, C.R.P. Moraes1, I.P. Santos2, I.T. Borba Junior1, S.C. Huber2, S.A.L. Montalvao2, J.M. Annichino-Bizzacchi1,2, A. C. Palma1, R. G. Ulaf1, A.F. Bernardes1, E. Mansour1, M.L. Moretti1, L.A. Velloso1,3, E.V. De Paula1,2

  • Abstract Number: PB0268

    Circulating Nucleosome Immunoassay: Evaluating a Clinically-applicable Test to Risk Stratify COVID-19 and Target Anticoagulation

    C. Rea1, S. Napoli1, S. Mujib1, F. Trovato1, A. Zamalloa1, J. Smith1, D. Nagra1, K. O'Gallagher1, M. McPhail1

  • Abstract Number: OC 31.2

    Clinical and Biological Assessment of the Largest Family with SRC-RT due to p.E527K Gain-of-Function Variant

    N. Revilla1, V. Palma-Barqueros2, A. Galera3, C. Zaninetti4, N. Bohdan2, A. Rodriguez-Alén5, A. Sánchez-Fuentes2, A. Marin-Quilez6, A. Zamora-Canovas2, V. Vicente2, A. Greinacher4, M.L. Lozano2, J.M. Bastida6,7, J. Rivera2,7

  • Abstract Number: LPB0080

    Clinical and Biological Assessment of the Second Pedigree Affected with X-linked GATA-1 Related Thrombocytopenia and Blood Group Lutheran Null

    A. Rodriguez-Alén1, V. Palma-Barqueros2, N. Rollón-Simón1, N. Revilla3, N. Bohdan2, J. Padilla2, A. Zamora-Cánovas2, A. Marín-Quílez4, A. Sánchez-Fuentes2, J.R. González-Porras4, V. Vicente2, J. Cuesta1, M.L. Lozano2, J.M. Bastida4,5, R. Pozo2,5

  • Abstract Number: PB0693

    Clinical and Genetic Analysis of Nine Cases of Hereditary Factor V Deficiency

    D. Zhang1, X. Zhang2, R. Yang1

  • Abstract Number: PB1158

    Clinical and Molecular Characterization of Chinese Patients with Protein S deficiency

    X. Zhang1, D. Zhang2, R. Yang2, F. Zhou1

  • Abstract Number: PB0409

    Clinical and Molecular Characterization of Iranian Patients with Congenital Qualitative Fibrinogen Disorders

    S. Mohsenian1, A. Azarkeivan1, M. Mirakhorli2, M. Jazebi2, O. Seidizadeh3.

  • Abstract Number: PB0646

    Clinical and Pharmacokinetic Assessment after Switching to an Extended Half-life Product for Prophylaxis in Haemophilia B

    K.I. Álvarez Tosco1, M.Á. Ocaña Gómez1, A.M. Ríos de Paz1, M.D. De Dios García1, M.C. Mesa Lorenzo1, J. Merino Alonso1

  • Abstract Number: PB0873

    Clinical Application of Genetic Testing in Patients with Not Acquired Thrombocytopenia: One Center Experience

    P. Silva de Tena1, M. Argüello-Tomás1, C. Pascual Izquierdo1,2,3, J.L. Díez-Martín1,2,3, C. Martinez Laperche1,2,3, G. Perez Rus1,2,3

  • Abstract Number: PB0629

    Clinical Assessment with the Evaluation of Joint Disease and Haemostatic Treatment in Patients with Severe Haemophilia B

    A. Buczma1, E. Odnoczko2, B. Baran2, A. Gwozdowska1, J. Zawilski3, J. Windyga1

  • Abstract Number: PB0473

    Clinical Characteristics and Incidence of Inhibitors in Previously Untreated Children with Haemophilia: An Update of the Hemfil Cohort Study

    L.L. Jardim1,2, M. Antônio Portugal Santana33, D. Gonçalves Chaves4, L. Werneck Zucheratto1, M. Hermida Cerqueira5, C. Santos Lorenzato6, V. Franco7, J. van der Bom2, S. Meireles Rezende1

  • Abstract Number: OC 44.1

    Clinical Characteristics and Prognosis of Antiphospholipid Syndrome Patients Based on Cluster Analysis: A 10-year Cohort Study

    W. Qi1, J. Zhao1,2, X. Tian1,2, M. Li1,2, X. Zeng1,2

  • Abstract Number: PB0433

    Clinical Characteristics of Acquired Haemophilia A Patients in 5 European Countries

    I. Palau1, S. Brown1, A. Rosli2, E. Seth2

  • Abstract Number: PB0260

    Clinical Course of COVID-19 in Patients with Inherited Bleeding Disorders: An Interim Analysis of 28 Cases

    A. Sikorska1, E. Stefanska-Windyga2, J. Windyga1

  • Abstract Number: PB1051

    Clinical Course of Thrombotic Antiphospholipid Syndrome with Positive IgA Anticardiolipin or IgA β2-glycoprotein I

    L. Figueiredo1, B. Mazetto2, A.P. dos Santos2, B. Jacintho2, C. Vaz2, J.D. Oliveira3, G. Mesquita2, J. Annichino-Bizzachi2, F. Orsi2

  • Abstract Number: PB0775

    Clinical Factors Predicting Decrease in Hemoglobin Levels during Preoperative Autologous Blood Donation by Patients Undergoing Major Orthopedic Surgery

    S. Fujii1, Y. Watanabe1, A. Ito1.

  • Abstract Number: PB0287

    Clinical Impact of Immune Thrombocytopenic Purpura in the Context of SARS-CoV-2 Infection

    C. Tarniceriu1,2, L.L. Hurjui3, L. lozneanu2, C. Delianu4, I. Hurjui5

  • Abstract Number: PB1185

    Clinical Implications of V/Q SPECT Scans Being Inconclusive in 20% of Patients Referred on Suspicion of Pulmonary Embolism

    K. Medson1, A. Hassler2, R. Taeri2, M. Bagge3, P. Lindholm1, E. Westerlund1

  • Abstract Number: PB1216

    Clinical Observations in Patients with Cerebral Venous Sinus Thrombosis

    T.W Htut1, H.G Watson1, G. Mackay2, M.M Khan1

  • Abstract Number: PB0508

    Clinical Outcomes after Joint Surgery in Patients on Turoctocog Alfa Pegol Prophylaxis

    A. Tiede1, S. Shivamurthy2, P. Chowdary3

  • Abstract Number: PO116

    Clinical Outcomes and Natural History of Critical Limb Ischemia: A Real World Experience

    D. Ceccato1, S. Ragazzo1, F. Boscaro1, F. Ceccato1, G. Camporese1, G. Avruscio1

  • Abstract Number: OC 67.3

    Clinical Outcomes in Adults with Hemophilia B with and without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial

    F.W. Leebeek1, W. Miesbach2, M. Recht3, N.S Key4, S. Lattimore3, G. Castaman5, E.K Sawyer6,7, D. Cooper6,7, V. Ferriera6,7, S.W Pipe8, HOPE-B Investigators

  • Abstract Number: PB0195

    Clinical Outcomes of Prophylactic vs. Therapeutic Doses of Anticoagulation In COVID-19 Patients: A Systematic Review and Meta-analysis

    M.A. Elsebaie1, B. Baral1, T. Shrivastava1, M.J. Tariq1, D. Kumi1, M. Elsebaie2

  • Abstract Number: PB0492

    Clinical Profile and Bleeding Outcome of Pediatric Hemophilia A: The Royal Hospital’s Experience, Oman

    A. Al Rawahi1, F. Al Riyami2, I. Al Ghaithi3, H. Al Shukaili4, M. Al Abri4, A. Al Rawahi5

  • Abstract Number: PB0717

    Clinical Profile and Bleeding Outcome of Pediatric Rare Bleeding Disorders: The Royal Hospital’s Experience, Oman

    M. AL Saadi1, H. AL Hasani1, A. Al Roshdi1, A. Al Amri1, I. Al Ghaithi2

  • Abstract Number: PB0314

    Clinical Relevance of JAK2V617F on Patients with Philadelphia-negative Myeloproliferative Neoplasms

    R. Frikha1, H. Kamoun1

  • Abstract Number: PB1114

    Clinical Risk Factors for Venous Thromboembolism in Hematologic Malignancies

    A. López Sacerio1, N. Alvarez Basulto2, M. Acosta Alvarez1, M.C. Tejeda Ramón1

  • Abstract Number: PB0654

    Clinical Translatable Preconditioning for Platelet Gene Therapy in Murine Hemophilia A with Inhibitors

    Y. Chen1,2, J. Schroeder1, J. Li1,2, W. Jing1, J. Hu2, Q. Shi1

  • Abstract Number: OC 62.2

    Clinical Value of Early Assessment of Hyperfibrinolysis by Rotational Thromboelastometry during Postpartum Hemorrhage for the Prediction of Severity of Bleeding: A Multicenter Prospective Cohort Study in the Netherlands

    M. Tahitu1,2, P. Ramler1,2, A. Gillissen1,3,2, C. Caram-Deelder3,2, D.D. Henriquez3,1,2, M.P. de Maat4, J.J Duvekot5, J. Eikenboom6, K.W. Bloemenkamp7, T. van den Akker1,8,9, J.G van der Bom2,3

  • Abstract Number: PB0923

    Clinical, Economic, and Quality of Life Burden Associated with von Willebrand Disease (VWD) in Adults and Children: Systematic and Targeted Literature Reviews

    G. Castaman1, N. Jansen2, S. Santos2, E. Berntorp3

  • Abstract Number: LPB0118

    Clinically Meaningful and Long-term Improvements in Fatigue with the C3 Inhibitor Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria: Post-hoc Analyses from the PEGASUS Study Week 48

    D. Cella1, S.P. Sarda2, R. Hsieh3, J. Fishman2, Z. Hakimi4, K. Cutts3, W.R. Lenderking5

  • Abstract Number: PB1063

    Clinico-pathologic Characterization of Patients Tested for Antiphospholipid Syndrome at a Tertiary Care Hospital

    K. Sajeeve1, D. K.V1, V. V1, A. Catherine Jacob1, D. Sidharth1, D. Vidyadharan1

  • Abstract Number: PB0611

    Clinicopathological Parameters and Influence of Blood Group and von Willebrand Factor (vWF) Levels on Residual Factor VIII (FVIII) Levels in Haemophilia A Patients

    D. Ray1, N. Kumar1, J. Ahluwalia1, R. Das1, C. Hans1, A. Jain1, P. Malhotra1, D. Bansal1

  • Abstract Number: PB0426

    Co-delivery of Tissue Plasminogen Activator and Plasminogen Using Magnetically Powered Microwheels

    D. Disharoon1, D. Marr1, K. Neeves2

  • Abstract Number: PO177

    Coagulation Abnormalities At Presentation of Childhood Acute Lymphoblastic Leukemia

    A. Canbolat Ayhan1

  • Abstract Number: PB0108

    Coagulation Abnormalities in Patients without Congenital Bleeding Disorders: Analysis of Secondary Causes of Low Clotting Factors Levels

    A. Lorenzo Jambrina1, M. Mosquera Tapia1, A. Torres Tienza1, E. Zato Hernández1, V. Cardos Gómez1, P. Galán Álvarez1, C. Olivier Cornacchia1, J.A. Queizán Herández1

  • Abstract Number: PB0110

    Coagulation Activity of Circulating Microparticles in Patients with Cardiovascular Diseases

    A. Mazurov1, I. Zyuryaev1, A. Komarov1, T. Martynyuk1, N. Golubeva1, O. Antonova1

  • Abstract Number: PB0977

    Coagulation and Anticoagulation Factors Affecting Platelet Responses Independently of Thrombin and Fibrin

    I. De Simone1,2, J.M. Gibbins2, H. ten Cate1,3, J.W. Heemskerk1, C.I. Jones2, P.E. van der Meijden1,3

  • Abstract Number: LPB0071

    Coagulation Factor 5 (F5) Is an Estrogen-responsive Gene in Breast Cancer Cells

    M. Seierstad Andresen1, M. Sletten1, P.M. Sandset2,1, N. Iversen1, B. Stavik*1, M. Tinholt*1

  • Abstract Number: OC 77.2

    Coagulation Factor XII Signaling via uPAR- β1 Integrin Promotes Renal Tubular Senescence in Diabetic Nephropathy

    A. Elwakiel1, K. Shahzad1, I. Gadi1, D. Gupta1, R. Rana1, S. Kohli1, T. Renné2, B. Isermann1

  • Abstract Number: PB1197

    Coagulation Factors Levels during and after Anabolic Androgenic Steroid Use: Data from the HAARLEM Study

    E. Camilleri1, D.L. Smit2, N. van Rein1,3, S. Le Cessie1, O. de Hon4, M. den Heijer5, S.C. Cannegieter1,6, W. de Ronde2

  • Abstract Number: PB0084

    Coagulation Management Strategies in Cardiac Surgery: Viscoelastic tests

    I. Rodriguez Martin1, Isabel Rodriguez Martin

  • Abstract Number: PB0035

    Coagulation Potential, Electrophysiological Characteristics and Structural Remodeling due to Atrial Fibrillation in Young and Aged Goats

    E. D'Alessandro1, B. Scaf2, V. Sobota2, A. van Hunnik2, M. Kuiper2, J. Winters2, R. van Oerle1, H. Spronk1, F. van Nieuwenhoven2, H. ten Cate1, S. Verheule2, U. Schotten2

  • Abstract Number: LPB0024

    Coagulation-cancer Crosstalk; Von Willebrand Factor Contributes to Pro-invasive and Pro-angiogenic Properties in Breast Cancer Cells

    S. Patmore1, S. Pal Singh Dhami1, J. Castle2, C. C. Kirwan2,3, J. S. O'Donnell1, J. M. O'Sullivan1

  • Abstract Number: PB0740

    Coagulopathy in Multiple Myeloma

    K. Chasakova1, L. Slavik2, D. Starostka1, J. Úlehlová2, T. Papajik2, J. Minařík2

  • Abstract Number: PB0232

    Coagulopathy in Patients with Severe COVID-19

    R. Cacciola1, E. Gentilini Cacciola2, V. Vecchio3, E. Cacciola1

  • Abstract Number: PO148

    Cocktail of Inherited Hemostatic and Red Cell Disorders in Unrelated Families of Interior Sindh

    A. Naz1, M. Khanzada2

  • Abstract Number: PB1046

    Collagen Turnover Biomarkers in Atrial Fibrillation and their Use in Clinical Management and the Study of Inflammatory Pathogenesis

    K. Wieschhaus1, E. Bontekoe1, J. Fareed1, D. Hoppensteadt1, S. Mushabbar1, J. Goldstein1

  • Abstract Number: PB1031

    Combined Antiplatelet Therapy Reduces the Pro-inflammatory Properties of Activated Platelets

    A.C. Heinzmann1, D.M Coenen1, T. Vajen1, J.M. Cosemans1, R.R Koenen1

  • Abstract Number: PB0009

    Combined Focused Ultrasound and Electrohydraulic Shock Wave Thrombolytic Therapy Accompanied by Tissue Plasminogen Activator Administration Reduce Thrombus Content in the Arterial Atherothrombotic Stenosis

    H. Mehrad1,2, A. Foletti3,2

  • Abstract Number: PB0301

    Combining Artificial Neural Networks and Blood Tests to Diagnose Covid-19 Infection

    T.D. Martins1, S.D. Martins2, S.A.L. Montalvão2, M. Al Bannoud1, G.Y. Ottaiano1, L.Q. Silva2, S.C. Huber2, T.S.P. Diaz3, C.K. Wroclawski4, C.C. Filho4, R.M. Filho5, J.M. Annichino-Bizzacchi2

  • Abstract Number: PB0051

    Combining Heparin with a FX/FXa Aptamer to Reduce Thrombin Generation in Models of Cardiopulmonary Bypass and COVID-19 Associated Coagulopathy

    C.V. Chabata1,2, J.W. Frederiksen1, L.B. Olson2,3, I.A. Naqvi4, B.A. Sullenger1

  • Abstract Number: PB1013

    Common Cardiovascular Disease Polygenic Risk Scores for Arterial and Venous Disease Influence Different Platelet Reactivity Tests

    J. Grech1, M. Chan1,2, A. Lachapelle1, F. Thibord1, Z. Schneider1, P. Armstrong2, C. Wallace de Melendez1, T. Warner2, M.-H. Chen1, A. Johnson1

  • Abstract Number: PB0379

    Comparability of PT Determination with STA-NeoPTimal on STart and STart Max Semi-automated Instruments

    G. Le Goff1, M. Bouchain1, A. Carlo2, J. Beltran1

  • Abstract Number: OC 56.2

    Comparative Analysis of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B-domain Favours Readthrough-mediated Protein Output

    M.F. Testa1, S. Lombardi1, M. Ferrarese1, P. Radossi2, D. Belvini2, G. Castaman3, F. Bernardi1, M. Pinotti1, A. Branchini1

  • Abstract Number: PB1083

    Comparative Effectiveness of Alternative Bridging Therapies for Subtherapeutic INR in Patients with Left Ventricular Assist Devices

    G. Chung1, E. Salem2, E. Sippola3, S. Shore3, L. Baumann Kreuziger2, G. Barnes3

  • Abstract Number: PB1250

    Comparative Effectiveness of Oral Anticoagulants in Venous Thromboembolism: On-treatment Analysis in GARFIELD-VTE

    S. Haas1, H. Bounameaux2, A.E. Farjat3, W. Ageno4, J.I. Weitz5, S.Z. Goldhaber6, A.G.G. Turpie7, S. Goto8, P. Angchaisuksiri9, P. MacCallum3,10, H. Ten Cate11, E. Panchenko12, M. Carrier13, C.J. Sanchez Dias14,15, H. Gibbs16, P. Jansky17, G. Kayani3, S. Schellong18, P. Prandoni19, A.K. Kakkar3,20, on behalf of the GARFIELD-VTE investigators

  • Abstract Number: PB0471

    Comparative Recovery of FVIII Antigen with Various FVIII Therapeutic Concentrates Using an Improved 2nd Generation ELISA Kit

    R. Ni1, P. Erb1, J. Della Maestra1, H. Atkinson2, D. Foulon1, K.M Black3, H. Hoogendoorn1, D. Matino2,4

  • Abstract Number: PB0633

    Compare the Efficacy and Safety of Low-dose and Intermediate-dose Prophylactic Therapy in Adult Patients with Severe Hemophilia A, a Self-control Study

    h. 高华1, R. Chen1, S. Zhou1

  • Abstract Number: PB1177

    Comparing “Clinical Hunch” against Clinical Decision Scores (PERC Rule, Wells Score, Revised Geneva Score, YEARS Criteria) in Acute Pulmonary Embolism Diagnostics

    K. Medson1, J. Yu2, L. Liwenborg1, E. Westerlund1, P. Lindholm1

  • Abstract Number: PB1222

    Comparing Adherence of Low Molecular Weight Heparin versus Unfractionated Heparin for Thromboprophylaxis of Medical Inpatients

    M. Trybula1, Z. Ahart1, E. Stacy2

  • Abstract Number: PB0047

    Comparing the Real-world and Clinical Trial Bleeding Rates Associated with Anticoagulation Treatment for Atrial Fibrillation

    R. Buderi1, A. Yi2, P. Allen1, T. Bebi1, C. Vigna1, R. Jain1, A. Majumdar1, D. Bloomfield2, J. Salter2, D. Freedholm2, A. Galaznik1

  • Abstract Number: PB0390

    Comparison between Coagulation Factor Deficiencies versus Pharmacological Inhibition of Activated Coagulation Factors Using Clot Waveform Analysis

    Y. Fujimori1, M. Wakui2, H. Katagiri1, Y. Ozaki1, Y. Kondo1, S. Oka1, T. Nakagawa1, S. Nakamura1, M. Murata2

  • Abstract Number: PB1218

    Comparison of 0.9% Normal Saline (NS) Flush and Unfractionated Heparin (UFH) Flush for Maintenance of Central Venous Catheter Line Patency

    A.N. Landmesser1,2, R.J. Roberts2, R.P. Rosovsky3,4, M.E. Barra2

  • Abstract Number: PB0101

    Comparison of a Chromogenic vs. APTT-based Factor VIII Activity Assay in the Recovery of a Pegylated Factor VIII Replacement Therapy in Plasma Samples

    T. Quinton1, J. Fraser1, K.M Black1, A. Sadeghi-Khomami1

  • Abstract Number: OC 45.2

    Comparison of Alternative Viscoelastic Hemostatic Assays – Rotational Thromboelastometry versus Sonorheometry for Rapid Diagnosis in Trauma Patients: An Interim Analysis

    J.M. Wohlgemut1, A. Rossetto1, R. Davenport1

  • Abstract Number: LPB0015

    Comparison of D-dimer values at peak and trough concentrations of direct oral anticoagulants: result of D-dimer testing is not affected by plasma drug concentration

    S. Margetić1, I. Ćelap1, M. Razum1, R. Mihić1, S. Šupraha-Goreta2

  • Abstract Number: PB0344

    Comparison of Peak Plasma Concentrations of Apixaban in Adolescent and Adult Patients

    I. Celap1, S. Margetic1, J. Obuljen2, J. Lenicek Krleza2, I. Linarić2, M. Razum1, R. Mihic1

  • Abstract Number: PB0348

    Comparison of Platelet Counts Using Impedance, Optical and CD61-immunoplatelet Methods in Thrombocytopenic Patients

    T. Nguyen1, P.-L. Tran2, T. Tran1, T. Nguyen1, T. Nguyen1

  • Abstract Number: PB0004

    Comparison of Platelet Function Tests during P2Y12 Inhibition

    P.P. Wadowski1, J. Pultar1, C. Weikert1, B. Eichelberger2, I.M. Lang3, R. Koppensteiner1, S. Panzer2, T. Gremmel1,4

  • Abstract Number: PB0368

    Comparison of PT/INR Assessment with STA-NeoPTimal on an Automated and Semi-automated Test Platform

    S. Savigny1, F. Depasse2, A. Veyradier3

  • Abstract Number: PB1263

    Comparison of Real-world Effectiveness and Safety of Enoxaparin versus Tinzaparin or Dalteparin in Cancer Patients with Venous Thromboembolism. The RIETECAT Cohort Study

    M. Monreal1, J. Trujillo-Santos2, D. Farge-Bancel3, J.M. Pedrajas4, C. Gómez-Cuervo5, A. Ballaz6, A. Braester7, I. Mahé8

  • Abstract Number: PB0730

    Comparison of the Relative PAR1, PAR2 and PAR3 Cleavage Profiles by Thrombin, APC, Factor Xa and Factor VIIa

    A. Yamashita1,2, M. Taki2, J.H. Griffin1, L.O. Mosnier1

  • Abstract Number: PB0383

    Comparison of Visual Interpretation of the DOAC Dipstick Test with a Reader System for Rapid and Accurate Detection of Direct Oral Anticoagulants in Neurology and Cardiology – Interim Data from a Prospective Consecutive Comparative Study

    S. Margetić1, I. Ćelap1, D. Delić-Brkljačić2, J. Harenberg3,4, A. Lovrenčić-Huzjan5, P. Mioč6, S. Šupraha Goreta7

  • Abstract Number: PB0617

    Comprehensive Genotype Characterization in Non-severe Hemophilia A. Mutational Profile and Assessment of the Bleeding Phenotype in Argentine Patients

    L. Rossetti1, A.I. Woods2, A. Blanco3, J. Paiva3, V. Marchione1, C.P. Radic1, M.M. Abelleyro1, B. Ziegler1, K. Waisman1, M.L. Romero3, M.M. Casinelli3, A. Sánchez-Luceros2,3, C. De Brasi1,4

  • Abstract Number: PB1132

    Concurrent Atypical Thrombotic Complications of Acute Promyelocytic Leukemia (APL) in an Anticoagulated Patient: A Rare Case Report

    A. Ashwath1, A. Cordova Sanchez1, S. Rao1, R. Denley1

  • Abstract Number: PB0690

    Concurrent Use of Tranexamic Acid and Hormonal Therapy: Management of Heavy Menstrual Bleeding in Women with Inherited Bleeding Disorders

    A. Epstein1, O. Turan1, R. Abdul-Kadir1

  • Abstract Number: PB0935

    Congenital Bleeding Disorders in Adolescent Females Evaluated for Menorrhagia and Iron Deficiency Anemia

    A. Trillo1, R. Leeman1, J. Davis2, F.F. Corrales-Medina2

  • Abstract Number: PB0716

    Congenital Factor Vii Deficiency and Vacterl Association: An Unusual Combination

    A. Ramirez1, C. Lince-Rivera1, L. Florez1, A. Infante1, Y. Vargas1

  • Abstract Number: PB0704

    Congenital Factor XI Deficiency: A Single-center Retrospective Analysis of 80 Cases

    X. Wang1,2,3, D. Zhang1,4, X. Liu1, F. Xue1, W. Liu1, Y. Chen1, R. Fu1, L. Zhang1,2,3, R. Yang1,2,3

  • Abstract Number: PB0644

    Consistency Analysis and Data Validation Regarding Hospitalization among Hemophilic Patients from the Hemophilia Center of the Hematology Service of HC FMUSP – (2008-2018)

    A.C. Guersoni1, P. Villaça2, V. Rocha2, E. Trindade3, O.D. Luiz4

  • Abstract Number: OC 64.1

    Contact Activation and Coagulation in Residual Venous Obstruction

    A.F. Iding1,2, B. Kremers2, M. Nagy2, A. Pallares Robles2,3, R. van Oerle2, H. ten Cate1,2,4, H.M. Spronk2, A.J. ten Cate-Hoek1,2

  • Abstract Number: PB0141

    Contact System and Intrinsic Pathway Are Activated and Associated with Clinical and Laboratory Outcomes in COVID-19 Patients

    M.W Henderson1,2, F. Lima3, C.R.P. Moraes3, A. Ilich2,4, S. Huber5, S.A.L. Montalvao5, M.S. Barbosa3, A.C Palma3, R.G Ulaf3, L.C. Ribeiro3, A.F. Bernardes3, M.L. Moretti3, S. Strickland6, J.M Annichino-Bizzacchi3,5, F.A. Orsi3, E. Mansour3, L.A Velloso3,7, N.S Key1,2,4, E.V De Paula3,5

  • Abstract Number: PB0094

    Control of Anti-coagulant Treatment in Patients with Acute Stroke by the Results of the «Thrombodynamics» Test

    E. Klychnikova1, G. Ramazanov1, E. Tazina1, S. Abudeev1, A. Vyshlova1

  • Abstract Number: OC 42.3

    Controlled Knockdown of Fibrinogen with siRNA Modulates Fibrinogen-mediated Inflammation

    L.J. Juang1,2,3, W.S. Hur4, L.M. Silva5, A.W. Strilchuk1,2,3, J. Leung1,2,3, B. La Prairie3, J.P. Luyendyk6, P.R. Cullis3, T.H. Bugge5, M.J. Flick4, C.J. Kastrup1,2,3

  • Abstract Number: OC 02.2

    Controlled Long-term Knockdown of Plasminogen in Mice and Dogs using siRNA: Assessment of Phenotype and Toxicity

    A.W Strilchuk1,2, J. Leung1,2, W.S Hur3, S. Abrahams3, L.M Silva4, T.H Bugge4, P.R Cullis1, M.J Flick3, T.C Nichols3, C.J Kastrup1,2

  • Abstract Number: PB0376

    Correlation between Plasma Levels, Anti-FXa Activity and Coagulation Parameters in Real-world Patients on Treatment with Edoxaban

    M. Corrochano1, R. Acosta-Isaac1, S. Mojal1, N. Grabalosa1, M. Plaza1, B. Jiménez1, J.C. Souto1, MACACOD Proyect

  • Abstract Number: LPB0120

    Correlation between Procoagulant Platelets and Hypercoagulability in Lung Cancer Patients

    M. Schreuder1,2, E.E. Ramsay1,2, H. Campbell3, J. Simes1, M. Boyer4, A. Joshua5,6,7, V. Chin5,6,7, J. Young8,9,10, B. Brown2, V.M. Chen3,11, P.J. Hogg2,12

  • Abstract Number: PB0750

    Correlation between Serum PDGF-CC Levels with Clinical Stage of Colorectal Cancer

    E. Sundarita1, M. Syahrir1, N. Djamaludin1, Y.D. Andayani1, Z. Zulaikha1, E. Syahriana1

  • Abstract Number: PB0354

    Correlation between the Rosner Index with the Etiological Diagnosis of the Prolongation of the Activated Partial Thromboplastin Time (aPTT) in Asymptomatic Presurgical Patients

    B.L. Diaz Jordan1, V.B. Yepez Espinales1, G. Lopez de la Osa Garcia1

  • Abstract Number: PB0264

    Correlation of Coagulation Parameters with Prognosis of COVID-19

    O. Smirnova1, O. Matvienko1, N. Korsakova1, A. Lerner2, T. Shvedova2, O. Golovina1, L. Papayan1

  • Abstract Number: PB0947

    Correlation of VWF:Ab to VWF:Ag Ratio and Abnormal VWF Multimer Pattern

    M. Stuart1, D. Chen1, N. Heikal1, R. Pruthi1

  • Abstract Number: PB0678

    Cost-effectiveness Analysis of the Brazilian Immune Tolerance Induction Protocol with Recombinant Factor VIII and Prophylaxis with Bypassing Agents or Emicizumab

    R.M. Camelo1, S.M. Rezende1, J. Álvares-Teodoro2

  • Abstract Number: PB0341

    Cost-effectiveness of a Stepwise versus an All-in-One Approach to Diagnose Mild Bleeding Disorders

    F. Heubel-Moenen1, L. Ansems1, P. Verhezen2, R. Wetzels2, R. Straat2, Y. Henskens2, E. Beckers3, M. Joore4

  • Abstract Number: PB0600

    Cost-effectiveness of rFVIII Single-chain in an Italian Population of Hemophilia A Patients: The Veneto Experience

    E. Zanon1, S. Pasca1, P. Radossi2, E. Bonetti3, A.C. Giuffrida3, A. Tosetto4

  • Abstract Number: PB1050

    Could the Adjusted Version of the Global Antiphospholipid Syndrome Score (aGAPSS) Be a Useful Tool to Select Patients with Primary Obstetric Antiphospholipid Syndrome (POAPS) for Primary Thromboprophylaxis with Aspirin?

    S. Udry1, F. Aranda1, S. Perés Wingeyer1, S. Stephanie Morales Perez2, C. Belizna3, J. Alijotas-Reig4, E. Esteve-Valverde2, D.S. Fernández Romero5, J.O. Latino5, G. de Larrañaga1

  • Abstract Number: PB1097

    Could Thromboprophylaxis Influence the Clinical Course of Patients with Active Cancer? Preliminary Results from the ACT4CAT Study

    N. Tsoukalas1, A. Christopoulou1, E. Timotheadou1, A. Koumarianou1, I. Athanasiadis1, S. Peroukidis1, G. Samelis1, A. Psyrri1, N. Kapodistrias1, C. Kalofonos1, C. Andreadis1, A. Ardavanis1, E. Samantas1, A. Bokas1, V. Barbounis1, N. Kentepozidis1, D. Mavroudis1, A. Athanasiadis1, P. Papakotoulas1, I. Boukovinas1

  • Abstract Number: PO138

    COVID-19 and Coagulation Abnormalities Diagnostic Dilemma

    N. Odeleye1, N. Kennedy1, P. Shinde1

  • Abstract Number: NUR 01.2

    COVID-19 and its Impact on the Pediatric Bleeding Disorders Population: Soaring BMIs

    V. Bouskill1, D. Tetzlaff1, C. Malcolmson1, C. Wakefield1, M. Carcao1

  • Abstract Number: PB0194

    COVID-19 and Patients with Hemorrhagic Congenital Disease: Experience from Regional Heamophilia Treatment Center of Strasbourg (France)

    M. Wald1, O. Feugeas1, D. Desprez1

  • Abstract Number: PB0178

    COVID-19 Diagnosis and its Impact on Thrombotic Risk in a Cohort of Consecutive Patients Hospitalized due to Severe Acute Respiratory Syndrome

    A. Coy Canguçu1, G. Aparecida Locachevic2, J.C. Silva Mariolano2, K.H. de Oliveira Soares2, J.D. Oliveira2, C. de Oliveira Vaz2, G. Vieira Damiani2, B. Mazetto2, J. Annichino-Bizzacchi2, E. V. de Paula2, F. Andrade Orsi2

  • Abstract Number: PB0179

    COVID-19 Infection is Associated with Antibody-mediated Procoagulant Platelets: Data from an Observational Study

    K. Althaus1,2, I. Marini1, J. Zlamal1, H. Häberle3, M. Mehrländer3, L. Pelzl1, A. Singh1, S. Hammer2, M. Bitzer4, N. Malek4, D. Rath5, H. Bösmüller6, M. Gawaz5, P. Rosenberger3, T. Bakchoul1,2

  • Abstract Number: PB0188

    COVID-19 Pneumonia Worse Prognosis Related to Lupus Anticoagulant Transient Positive Test

    J.M. Ceresetto1, S. Rivarola2, C. Duboscq1, M. Carreras1, A. Cantillo1, L. Zapata1, K. Oliveros1, A. Avila1, C. Sernaque1, M. Quarchioni1, N. Flegler1, S. Palmer1, G. Stemmelin1

  • Abstract Number: PB0183

    COVID-19 Related Abnormalities in the Hematologic Characteristics among Inpatient Children. Results of the PICNIC Registry

    S. Tehseen1, J. Robinson2, S. Williams3, L. Lieberman4, PICNIC Paediatric Investigator Collaborative Network on Infections in Canada

  • Abstract Number: PB0177

    COVID-19 Vaccination and Anticoagulation: Potential Effects on Anticoagulation Control in Patients Using Vitamin K Antagonists

    C. Visser1, J.S. Biedermann1, M.C. Nierman2, F.J.M. van der Meer3, S.C. Cannegieter3,4, W.M. Lijfering4, M.J.H.A. Kruip1

  • Abstract Number: PB0165

    COVID-19-Related Thrombosis in Japan: Results of a Questionnaire-based Survey in 2020

    H. Horiuchi1, E. Morishita2, T. Urano3, K. Yokoyama4, - The Questionnaire-Survey Joint Team on the COVID-19-Related Thrombosis5,6,7

  • Abstract Number: OC 29.3

    CRISPR Edited Megakaryocytes for Rapid Screening of Platelet Gene Functions

    E. Montenont1, S. Bhatlekar1, S. Jacob1, Y. Kosaka1, B. Manne1, O. Lee1, I. Parra-Izauierdo2, E. Tugolukova1, N. Tolley1, M. Rondina1, P. Bray1, J. Rowley1

  • Abstract Number: PB0255

    Cross-talk between the Inflammatory Response and Coagulopathy: Single-center Report

    Y.B. Tor1, S. Kalayoglu Besisik2, M. Ozbalak2, M. Kose1, A. Medetalibeyoglu1, N. Senkal1, A. Cagatay3, S. Simsek Yavuz3, A. Gul4, M. Erelel5, F. Esen6, T. Tukek1

  • Abstract Number: OC 01.1

    Crosstalk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H

    C. Puy1, J. Pang1, S.E Reitsma1, C.U Lorentz1, E.I Tucker1, D. Gailani2, A. Gruber1, F. Lupu3, O. J.T. McCarty1

  • Abstract Number: OC 42.4

    Cryoprecipitate Transfusion Significantly Decreases the Rate of Plasmin Generation in Trauma Patients

    G.B Morrow1,2, M.SA Carlier2, S. Dasgupta2, F.B Craigen2, C.S Whyte2, J. Winearls3, M.A Laffan4,5, N.J Mutch2, N. Curry1,5

  • Abstract Number: OC 26.2

    Cryoprecipitate, and Not Fibrinogen Concentrate, Enhances Early Clot Formation in an in vitro Microfluidic Model of Dilutional Coagulopathy

    S. Shea1, K. Thomas1, P. Spinella1

  • Abstract Number: OC 05.1

    Crystal Structure of Factor IXa with an Anticoagulant Aptamer Bound to an Allosteric Site

    V. Kolyadko1, J. Layzer2, B. Sullenger2, S. Krishnaswamy1,3

  • Abstract Number: OC 09.2

    Crystal Structure of the von Willebrand Factor A1 Domain – Caplacizumab Complex

    A. Brown1, J. Emsley1, N. Arce2, R. Li2

  • Abstract Number: PB1105

    Cumulative Incidence of Recurrent Venous Thromboembolism by Cancer and Provoking Status – A Population-based Study

    K. Ding1, L. Ford1, A. Wendelboe1, A. Adamski2, N. Reyes2, K. Abe2, G. Raskob1

  • Abstract Number: PB1028

    Curcumin Inhibits Platelets by Activation of Adenosine A2 Receptor and cAMP/PKA Pathway

    N. Rukoyatkina1, N. Al Arawe2, S. Gambaryan1, V. Shpakova1

Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley